Caigang Liu: Clinical Trials

4 trials sponsored by Caigang Liu, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 active not recruiting, 1 enrolling by invitation, 1 not yet recruiting, 1 recruiting. 2 Not applicable, 2 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Not applicable2Enrolling by invitation 1, Not yet recruiting 1
Phase 32Active not recruiting 1, Recruiting 1
Phase 21Active not recruiting 1

Follow Caigang Liu: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Efficacy and Safety of Sanyong Jiedu Granules in Treating Lumps-Type Non-Lactational Mastiti
Sanyong Jiedu Granules, Standard Medication - Plasmacytic Mastitis, Granulomatous Lobular Mastitis
Not applicableNot yet recruitingCaigang Liu2102026-03-202026-04-06
Real-world Study on Shenbailing Granules for Improving Qi and Blood Deficiency in Patients After Breast Cancer Surgery
Shenbailing - Breast Cancer
Not applicableEnrolling by invitationCaigang Liu20002024-12-302025-03-18
Cadonilimab (AK104) Combined With Chemotherapy and Bevacizumab as First-line Treatment for RAS Mutated or Right Sided-metastatic MSS Colorectal Cancer
Cadonilimab (AK104) combined with chemotherapy and bevacizumab - Colorectal Cancer
Phase 3RecruitingCaigang Liu302024-02-012024-08-22
A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients
ARX788, Pyrotinib maleate, Trastuzumab - HER2-positive Breast Cancer
Phase 2 / Phase 3Active not recruitingCaigang Liu1362022-05-232024-10-30

Conditions studied

Breast Neoplasms (1)  ·  Colorectal Neoplasms (1)

Interventions

ARX788 (1)  ·  Bevacizumab (1)  ·  Carboplatin (1)  ·  Docetaxel (1)  ·  Drug Therapy (1)  ·  Trastuzumab (1)  ·  pertuzumab (1)

Countries

China (4)